Phathom Pharmaceuticals, Inc. (PHAT): Total Assets
$259.15M
As of 2025-12-31
$327.07M
As of 2026-06-30
+16.3%
3-year compound annual growth
-2.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $259.15M | -31.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $378.32M | -8.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $413.84M | +151.1% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $164.81M | -13.0% | 2024-06-14, Balance as of period end |
| 2021-12-31 | $189.43M | -35.8% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $295.11M | +14.7% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $257.18M | n/m | 2021-03-30, Balance as of period end |
| 2018-12-31 | $902.0K | n/a | 2020-03-19, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $259.15M | -31.5% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $418.43M | +54.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $255.88M | +9.7% |
Compare PHAT, CYRX, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗